Viewing Study NCT07302360


Ignite Creation Date: 2025-12-25 @ 2:08 AM
Ignite Modification Date: 2025-12-26 @ 4:31 AM
Study NCT ID: NCT07302360
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2025-12-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
Sponsor: Xian-Janssen Pharmaceutical Ltd.
Organization:

Study Overview

Official Title: Guselkumab Real-world Effectiveness Among Bio-NaÏve Patients With Moderate-to-severe Ulcerative Colitis in China: A Multicenter, Non-interventional, Prospective Study
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GENIUS
Brief Summary: The purpose of this study is to assess the measurable changes in health, function, or quality of life (clinical outcomes) after receiving guselkumab in real-world clinical practice amongst Chinese participants with ulcerative colitis (UC; a long-term disease of the large intestine in which the lining of the colon \[part of large intestine\] becomes inflamed and develops tiny open ulcers), who have not received biologic therapy (a medicine made from living organisms or their components) previously.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
CNTO1959UCO4003 OTHER Janssen Research & Development, LLC View